Haemonetics Co. (NYSE:HAE) EVP Michelle L. Basil Sells 7,187 Shares

Haemonetics Co. (NYSE:HAE) EVP Michelle L. Basil sold 7,187 shares of Haemonetics stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $103.49, for a total value of $743,782.63. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of HAE opened at $110.07 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.44 and a quick ratio of 1.62. The firm has a market capitalization of $5.54 billion, a price-to-earnings ratio of 45.24, a price-to-earnings-growth ratio of 2.74 and a beta of 0.67. Haemonetics Co. has a fifty-two week low of $80.24 and a fifty-two week high of $117.56.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.06. The company had revenue of $249.30 million during the quarter, compared to the consensus estimate of $250.62 million. Haemonetics had a return on equity of 18.88% and a net margin of 5.69%. Haemonetics’s revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.43 EPS. On average, analysts forecast that Haemonetics Co. will post 2.93 EPS for the current year.



Several research analysts have weighed in on the company. TheStreet upgraded Haemonetics from a “c+” rating to a “b-” rating in a report on Tuesday, May 7th. Zacks Investment Research upgraded Haemonetics from a “sell” rating to a “hold” rating in a report on Tuesday, April 9th. Raymond James upgraded Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price target for the company in a report on Tuesday, May 14th. Finally, Barrington Research reiterated an “outperform” rating and issued a $116.00 price target (up from $112.00) on shares of Haemonetics in a report on Wednesday, May 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $118.60.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Financial Gravity Companies Inc. acquired a new stake in shares of Haemonetics during the 4th quarter worth $41,000. NumerixS Investment Technologies Inc increased its holdings in shares of Haemonetics by 500.0% during the 1st quarter. NumerixS Investment Technologies Inc now owns 600 shares of the medical instruments supplier’s stock worth $52,000 after buying an additional 500 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in shares of Haemonetics by 708.8% during the 1st quarter. Quadrant Capital Group LLC now owns 647 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 567 shares during the last quarter. Ellis Investment Partners LLC acquired a new stake in shares of Haemonetics during the 1st quarter worth $79,000. Finally, Ffcm LLC increased its holdings in shares of Haemonetics by 134.4% during the 4th quarter. Ffcm LLC now owns 1,744 shares of the medical instruments supplier’s stock worth $174,000 after buying an additional 1,000 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Haemonetics Co. (NYSE:HAE) EVP Michelle L. Basil Sells 7,187 Shares” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://dakotafinancialnews.com/2019/06/13/haemonetics-co-nysehae-evp-michelle-l-basil-sells-7187-shares.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Article: Using other technical indicators with support levels

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.